课题基金 / 基金详情

Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study

Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study
托莫西汀治疗 ADHD/PTSD 共病:一项安慰剂对照的试点可行性研究
批准号:
8819168
负责人:
ZHEWU WANG
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-12-01 至 2016-11-30

项目摘要

项目成果

ZHEWU WANG的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供): 患有创伤后应激障碍(PTSD)的退伍军人通常在注意力、工作记忆、执行功能和抑制控制方面表现出认知障碍,这是一系列类似ADHD症状的症状。合并ADHD认知症状的存在往往与更严重的PTSD临床严重程度和更差的治疗结果相关。虽然军事人员的回避、觉醒和与创伤后应激障碍相关的症状的治疗是现成的,但在与创伤后应激障碍相关的认知缺陷的治疗方面存在很大差距。因此,创伤后应激障碍中未经治疗的ADHD认知症状可能会对患者的功能恢复、治疗结果和生活质量产生严重的负面影响。鉴于高达50%的患者对一线PTSD治疗反应不佳,寻求新的认知改善治疗策略势在必行,这将改善标准治疗反应和日常功能恢复。这项拟议的研究通过测试托莫西汀(ATX)在减少患有ADHD/PTSD的退伍军人中的ADHD认知症状的有效性,直接解决了这一知识差距。ATX是FDA批准用于治疗ADHD的非刺激性选择性去甲肾上腺素再摄取抑制剂(SNRI)。研究表明,与兴奋剂不同,ATX缺乏成瘾特性,在治疗抑郁症和焦虑症方面表现出疗效,这是治疗ADHD和PTSD的理想药物。这项应用的目的是检查ADHD认知症状对PTSD临床结果的影响,并评估ATX在增强患有PTSD/ADHD的退伍军人的认知功能、改善生活质量和治疗结果方面的有效性。我们最近的研究发现,患有创伤后应激障碍的退伍军人中ADHD症状的患病率(45%)高于没有创伤后应激障碍的老兵(11%),并且ADHD症状的共病与创伤后应激障碍的临床严重程度相关。在合并ADHD/PTSD的患者中,哌酸甲酯的治疗显示他们的学习和职业表现得到改善,PTSD的治疗结果也有所改善。根据我们的发现,我们假设1)合并ADHD症状是治疗抵抗的风险,2)ATX治疗将减少ADHD认知症状,促进功能恢复,并改善退伍军人的生活质量和PTSD治疗结果。为了实现我们的目标,我们的目标是:1)检查ADHD症状对患有PTSD的退伍军人的治疗反应的影响;2)评估附加ATX与安慰剂在缓解ADHD认知症状、改善认知功能和退伍军人生活质量方面的有效性和安全性;3)评估附加ATX与安慰剂在降低PTSD症状方面的疗效。为了实现这些目标,我们将对患有ADHD/PTSD的退伍军人进行一项试验性前瞻性、为期10周的固定剂量、随机、双盲、安慰剂对照和交叉试验,将其作为其他治疗方法的附加药物。主要结果指标将是ADHD认知症状的减少和生活质量的改善;次要结果指标将是创伤后应激障碍和抑郁症状的减少。本研究具有创新性,将新型治疗剂应用于创伤后应激障碍认知症状的治疗。据我们所知,这是第一项应用SNRI来解决经常被忽视的创伤后应激障碍认知缺陷的研究。我们的研究直接响应了RR&D-SPIRE的使命,即最大限度地恢复创伤后应激障碍患者的认知功能。拟议研究的结果将是重要的,因为它提供了一个知识库,帮助确定谁有可能在创伤后应激障碍患者中产生治疗耐药性,从而允许制定早期干预策略。更重要的是,新的知识可能会为创伤后应激障碍的新颖和更有效的治疗发现新的靶点。这项临床试验可能立即使退伍军人受益,因为他们增强了认知功能,减少了与残疾相关的ADHD症状,并进一步改善了患有ADHD/PTSD的退伍军人的生活质量。
英文摘要
DESCRIPTION (provided by applicant): Combat Veterans with posttraumatic stress disorder (PTSD) often show cognitive impairments in attention, working memory, executive functions, and inhibitory control, a cluster of symptoms resembling symptoms of ADHD. The presence of comorbid ADHD cognitive symptoms is often associated with greater PTSD clinical severity and poorer treatment outcomes. While treatments for the avoidance, arousal, and re-experiencing symptoms associated with PTSD for military personnel are readily available, substantial gaps exist in the treatment of the cognitive deficits associated with PTSD. As a result, untreated co-occurring ADHD cognitive symptoms in PTSD may have severe negative impacts on patients' functional recovery, treatment outcome, and quality of life. Given that up to 50% of patients do not respond well to the first-line PTSD treatments, it is imperative to seek novel treatment strategies toward cognitive improvement that will improve both standard treatment response and daily functional recovery. The proposed study directly addresses this knowledge gap by testing the efficacy of atomoxetine (ATX) in reducing ADHD cognitive symptoms among veterans with comorbid ADHD/PTSD. ATX is a non-stimulant selective norepinephrine reuptake inhibitor (SNRI), approved by FDA for treatment of ADHD. Studies suggest that ATX, unlike stimulant, lacks addictive properties and shows efficacy in the treatment of comorbid depression and anxiety, which is ideal in treatment of comorbid ADHD and PTSD. The objective of this application is to examine the impact of ADHD cognitive symptoms on PTSD clinical outcomes, and to assess the efficacy of ATX in enhancing the cognitive function, improving quality of life, and treatment outcomes in veterans with comorbid PTSD/ADHD. Our recent research uncovered a higher prevalence of ADHD symptoms among combat veterans with PTSD (45%) than among those without PTSD (11%), and the comorbid ADHD symptoms was correlated with PTSD clinic severity. Treatment with methylphenidate showed improvement in their academic and occupational performance, and improvement in the PTSD treatment outcome in patients with comorbid ADHD/PTSD. Based on our findings, we hypothesize that 1) comorbid ADHD symptoms is a risk for treatment resistance, and 2) treatment with ATX will reduce ADHD cognitive symptoms, facilitate functional recovery, and improve veterans' quality of life and PTSD treatment outcomes. To accomplish our objective, we aim to: 1) examine the impact of ADHD symptoms on treatment response in Veterans with PTSD; 2) assess the efficacy and safety of add-on ATX as compared with placebo in relieving ADHD cognitive symptoms, improving cognitive function and veterans' quality of life; 3) evaluate the efficacy of add-on ATX as compared with placebo in reducing PTSD symptoms. To achieve these aims, we will conduct a pilot prospective, 10-week, fixed-dose, randomized, double-blind, placebo-controlled, and cross-over trial of ATX as an add-on medication to other therapies in Veterans with comorbid ADHD/PTSD. Primary outcome measures will be ADHD cognitive symptom reduction and quality of life improvement; and the secondary outcome measures will be PTSD and depressive symptoms reduction. The proposed work is innovative; it applies novel therapeutic agent to treat cognitive symptoms in PTSD. To our knowledge, this is the first study to apply a SNRI to address an often overlooked PTSD-cognitive deficit. Our research is directly responsive to the mission of RR&D-SPiRE "to maximize functional recovery" of cognitive function in PTSD. The outcome of the proposed research will be significant, because it provides a knowledge base to help determine who is at risk for developing treatment resistance among PTSD patients, thereby allowing for development of early intervention strategies. More importantly, the new knowledge may lead to discovering new targets for novel and more effective treatments for PTSD. This clinical trial may immediate benefit Veterans by enhancing their cognitive function, reducing ADHD symptoms related disability, and further improving quality of life for veterans suffer from comorbid ADHD/PTSD.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Dysregulated Immune State in PTSD Contributes to Microglial Inflammation
Cortical Excitability: Biomarker and Endophenotype in Combat Related PTSD
Cortical Excitability: Biomarker and Endophenotype in Combat Related PTSD
Cortical Excitability: Biomarker and Endophenotype in Combat Related PTSD
海外基金